FDA Reprimand to Novartis Over Misleading Ad

Howie and Harlan are joined by Yale SOM alum Claudine Litman, a designer and the director of Yale's Center for Outcomes Research & Evaluation, to talk about using the tools of design to build more effective healthcare spaces and processes. Harlan looks at seven charts illustrating the state of healthcare in 2023; Howie reports on the FDA reprimanding a drug company for misleading advertising.

Links:

Healthcare in 2023

"Seven Charts That Sum Up U.S. Healthcare In 2023"

Designing Better Healthcare

Yale School of Medicine:Center for Outcomes Research & Evaluation

Design for Care: Innovating Healthcare Experience

This Is Service Design Doing: Applying Service Design Thinking in the Real World

The Design of Business: Why Design Thinking is the Next Competitive Advantage

Misleading Advertising

"FDA scolds Novartis over a misleading TV ad for a breast cancer treatment"

Public Law 87-781, 76 STAT 780

FDA: Letter to PharmD

Direct-to-Consumer Prescription Drug Advertisements: Presentation of the Major Statement in a Clear, Conspicuous, and Neutral Manner in Advertisements in Television and Radio Format Final Rule Questions and Answers Guidance for Industry

NIH: Direct-to-Consumer Pharmaceutical Advertising

Learn more about the MBA for Executives program at Yale SOM.

Email Howie and Harlan comments or questions.